Navigation Links

MISSISSAUGA, ON, May 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that posters describing research conducted on its pain management product AeroLEF(TM) will be presented at The 27th Annual Scientific Meeting of the American Pain Society, which takes place May 8-10, 2008 in Tampa, Florida.

The first poster presentation, entitled "A randomized controlled trial demonstrates the efficacy, safety and tolerability of Aerosolized free and Liposome-Encapsulated Fentanyl (AeroLEF(TM)) via pulmonary administration", is scheduled to be presented on Thursday, May 8, 2008 (Abstract #8448, Poster Board number 265).

The second poster presentation, entitled "Comparative phase I PK study of Aerosolized free and Liposome-Encapsulated Fentanyl (AeroLEF(TM)) demonstrates rapid and extended plasma fentanyl concentrations following inhalation", is scheduled to be presented on Thursday, May 8, 2008 (Abstract # 8395, Poster Board number 243).

The third poster presentation, entitled "Aerosolized Liposome-Encapsulated Fentanyl (AeroLEF(TM)) via pulmonary administration allows patients with moderate to severe post-surgical acute pain to self-titrate to effective analgesia", is scheduled to be presented on Friday, May 9, 2008 (Abstract # 8435, Poster Board number 264).

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(TM) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pressure BioSciences, Inc. to Discuss First Quarter 2008 Financial Results and Provide Business Update
2. Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
3. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
5. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
6. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
8. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
9. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
10. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
11. Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf ... the 2016 USGA Green Section Award. Presented annually since 1961, the USGA Green Section ... her work with turfgrass. , Clarke, of Iselin, N.J., is an extension ...
(Date:11/24/2015)... 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or "the ... results for the quarter ended September 30, 2015. ... dollars and presented under International Financial Reporting Standards ... ," said Andrew Rae , President & ... are not only value enriching for this clinical ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... This fall, ... at competitive events in five states to develop and pitch their BIG ideas to ... from each state are competing for votes to win the title of SAP's Teen ...
Breaking Biology Technology:
(Date:11/18/2015)... , Nov. 18, 2015  As new scientific discoveries ... doctors and other healthcare providers face challenges in better ... and patients. In addition, as more children continue to ... patient,s adulthood and old age. John M. ... Children,s Hospital of Philadelphia (CHOP) . --> ...
(Date:11/17/2015)... 17, 2015  Vigilant Solutions announces today that Mr. ... of Directors. --> --> ... from the partnership at TPG Capital, one of the ... $140 Billion in revenue.  He founded and led TPG,s ... TPG companies, from 1997 to 2013.  In his first ...
(Date:11/12/2015)... Mass. , Nov. 12, 2015  Arxspan ... Institute of MIT and Harvard for use of ... discovery information management tools. The partnership will support ... both biological and chemical research information internally and ... will be used for managing the Institute,s electronic ...
Breaking Biology News(10 mins):